[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Khandekar et al., 2018 - Google Patents

Noncanonical agonist PPARγ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy

Khandekar et al., 2018

View HTML @Full View
Document ID
13684635871355869125
Author
Khandekar M
Banks A
Laznik-Bogoslavski D
White J
Choi J
Kazak L
Lo J
Cohen P
Wong K
Kamenecka T
Griffin P
Spiegelman B
Publication year
Publication venue
Proceedings of the National Academy of Sciences

External Links

Snippet

The peroxisome-proliferator receptor-γ (PPARγ) is expressed in multiple cancer types. Recently, our group has shown that PPARγ is phosphorylated on serine 273 (S273), which selectively modulates the transcriptional program controlled by this protein. PPARγ ligands …
Continue reading at www.pnas.org (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins

Similar Documents

Publication Publication Date Title
Khandekar et al. Noncanonical agonist PPARγ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy
Nilsson et al. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
Echeverria et al. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state
Zhang et al. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody
Januario et al. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors
Xu et al. Targetable BET proteins-and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma
Venere et al. The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma
Lin et al. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer
Rebello et al. Therapeutic approaches targeting MYC-driven prostate cancer
Weiler et al. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy
Genini et al. Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells
Kashatus et al. Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth
Gujral et al. Hippo pathway mediates resistance to cytotoxic drugs
Schito et al. Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
Wang et al. Polyploidy road to therapy‐induced cellular senescence and escape
Halliday et al. In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift
Zirath et al. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells
Zhang et al. Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Janghorban et al. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer
Furic et al. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression
Shackelford et al. mTOR and HIF-1α-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome
Woditschka et al. DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer
Abe et al. Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2
Xu et al. BCL6 promotes glioma and serves as a therapeutic target
Zhang et al. TRIM39 regulates cell cycle progression and DNA damage responses via stabilizing p21